Aubrey Crispen, Athens: She hammered two home runs and drove in five as Athens topped Petersburg PORTA 11-6 in a Sangamo ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Five Below’s stocks faced a heavy downturn, plummeting 27.81% to finish at $58.83. The steep drop coincided with overarching market fears stemming from President Donald Trump's tariff plan, which ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal with pharma major Eli Lilly (NYSE: LLY), sending its share up 24% to $0.77.

Eli Lilly’s stock slipped during a broader market nosedive sparked by Trump’s tariff barrage, but retail traders oddly found reasons to cheer. The pharmaceutical sector mostly dodged the tariff bullet ...

Eli Lil­ly is li­cens­ing Sang­amo Ther­a­peu­tics’ AAV cap­sid for an undis­closed CNS dis­ease tar­get, and the $18 mil­lion up­front fee should give the be­lea­guered biotech … ...